James R Klinger (Rhode Island Hospital, and Warren Alpert Medical School, Brown University, Providence, RI, US) chats to us on the topic of his session entitled: Current Quandaries in Pulmonary Arterial Hypertension (PAH) Management.
1. What are the major challenges in the management of pulmonary arterial hypertension (PAH)? (0:10)
2. What have been the most important recent developments in PAH therapy? (0:44)
3. What are the pros and cons of front line combination therapy versus sequential therapy? (1:22)
4. What is the role of oral anticoagulation therapy in the management of PAH? (2:17)
5. What are the major gaps in our knowledge of PAH management that require addressing? (2:53)
Speaker disclosure: James R Klinger’s institution receives grant support from Actelion, Bayer, Eiger BioPharmaceuticals, Lung International and United Therapeutics.
Filmed at the CHEST Annual Meeting, San Antonio, TX, US, October 2018.
Share this Video
Related Videos In Pulmonary Hypertension
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]
Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!